T-cell costimulatory blockade as a constituent for recipient conditioning prior to bone marrow transplantation has led to the development of less toxic protocols for the establishment of donor cell chimerism. We therefore hypothesized that the addition of the hematopoietic growth factor, Flt3-ligand (Flt3-L), to the perioperative inhibition of the CD28/B7 and CD40/CD40 ligand costimulatory pathways would enhance the engraftment of allogeneic bone marrow. Recipient BALB/c ByJ (H-2 d , Mls c , Vβ6 + /Vβ8 + TCR) received a single sublethal dose of total body irradiation (300 rad) 6 h prior to transplantation IV with unfractionated donor CBA/J (H-2 k , Mls d , Vβ6 − /Vβ8 + TCR) bone marrow cells. CTLA4-Ig and/or MR1 were administered at 500 µg IP on days 0, 2, 4, and 6 posttransplantation. Flt3-L was administered at 10 µg IP on days 0-6. Donor cell chimerism was determined on days 30-90 by flow cytometric analysis. Donor-specific tolerance was assessed by skin grafting. In vitro TCR cross-linking assays and flow cytometry were utilized to explore the deletion of donor-reactive T cells. Recipients receiving CTLA4-Ig and MR1 engrafted allogeneic bone marrow cells in the peripheral blood (3/6; 50%) with chimerism being detected at 2-31%. Addition of Flt3-L to this preconditioning regimen enhanced the incidence of engraftment of donor bone marrow cells (10/13; 3-70%). Long-term survival of donor but not third-party-specific skin grafts demonstrated that donorspecific tolerance had been achieved in the chimeric recipients. Deletion of the donor-reactive T cells within the chimeric recipients was also observed. The addition of hematopoietic growth factors and cytokines to the nonmyeloablative regimen of sublethal irradiation and T-cell costimulatory blockade provides a novel strategy for the establishment of donor cell chimerism and for the induction of stable and robust donorspecific tolerance. The deletion of donor-reactive T cells using this protocol suggests the reliability and feasibility of this protocol for clinical transplantation.
INTRODUCTION
gration between the donor and recipient leads to rejection or to the acceptance of allogeneic organs depends on the quality of immunosuppression, the quantity and The induction of robust and stable donor-specific tolerance (DST) without continuous immunosuppression type of immune cells within the transplanted tissue, donor-recipient histoincompatibility, and possibly addi-remains the ultimate goal in experimental and clinical transplantation (Tx) with many immunological require-tional undefined factors (30) . Even though numerous explanations have been proposed, the migration of donor ments and mechanisms having been postulated for achieving this outcome (14, 38) . Mixed chimerism, the cohabi-leukocytes from the transplanted organ to the periphery of the recipient and the function of mixed chimerism in tation of both donor and recipient leukocytes within a transplanted recipient, is one such example that has been the induction and maintenance of tolerance remain ill defined (14, 38) . suggested to be associated with long-term allograft acceptance, to be actively participating in the induction and/or Various strategies have been employed in both experimental animal models and humans for inducing a state maintenance of tolerance (unresponsiveness), and in some circumstances has led to the reduction or withdrawal of of tolerance with variable success (14, 38) . Earlier reports have demonstrated that donor cell chimerism can immunosuppression (14, 24, (29) (30) (31) 38, 44) . Whether cell mi-148 WOODWARD ET AL. be easily achieved in experimental models of bone mar-lishment of donor cell chimerism (4, 6, 7, 9, 12, 16, 18, 19, 28, 39, (40) (41) (42) . It has been demonstrated in our labora-row Tx (BMTx), and with proper conditioning of the recipient, provides a feasible strategic option for induc-tory as well as in others that the addition of CTLA4-Ig and anti-CD40L mAb with sublethal irradiation and do-ing DST (4, 6, 7, 9, 10, 12, 16, 18, 19, 28, 37, (39) (40) (41) (42) . A variety of methods, which have included irradiation, cyto-nor BM infusion results, in the majority of the animals, in the establishment of stable and robust donor cell chi-ablative drugs, and surgical removal of lymphoid organs, have been successfully utilized to condition the recipient merism and ultimately in the induction of DST (4, 12, 16, 18, 19, 28, 36, 40, 41) . Because Flt3 (fms-like tyrosine for the engraftment of allogeneic bone marrow (BM) (38). To prevent the deleterious effects of eliminating kinase 3) ligand (Flt3-L) is a potent growth factor with demonstrable effects on the recruitment and expansion the recipient's entire immune system, achieving low but persistent levels of donor cell chimerism, which mimics of hematopoietic progenitor and stem cells both in vivo and in vitro (1) , we elected to use this molecule along the natural microchimerism witnessed in transplant recipients, is a more advantageous approach, because the with the costimulatory blockade protocol in order to enhance engraftment of allogeneic BM with the potential recipient's immune system is available with the donorderived cells to provide immuncompetence in the pe-to promote chimerism and induce robust DST. Hence, we tested the hypothesis that the addition of Flt3-L to riphery and a continual source of antigen, respectively (38). The use of irradiation (sublethal) as a nonmy-the contemporaneous, perioperative inhibition of the CD28/B7 and CD40/CD40L T-cell costimulatory path-eloablative approach has been an effective strategy for the engraftment of allogeneic BM (38). However, it has ways enhances the engraftment of allogeneic BM. Stable and robust donor-specific tolerance was achieved in this been demonstrated that such treatment alone is insufficient for the establishment of donor cell chimerism and murine sublethal irradiation model of donor BMTx. The immunological functions and mechanisms were explored. for the induction of DST (38). Only when combined with other nonmyeloablative conditioning regimens has MATERIALS AND METHODS sublethal irradiation been successful in accomplishing Mice these goals (38).
It has been hypothesized that by eliminating or atten-Inbred 10-12-week-old male BALB/c ByJ (H-2 d , uating the immunoreactivity of donor-reactive T cells, Mls c , Vβ6 + /Vβ8 + TCR), CBA/J (H-2 k , Mls d , Vβ6 − /Vβ8 + the balance that is required between cell trafficking and TCR), and C57BL/6 (H-2 b ), purchased from Jackson the prevention of graft-versus-host disease (GVHD) or Laboratory (Bar Harbor, ME), were maintained in a allograft rejection for the induction of DST can be pathogen-free facility with Purina rodent chow and tap achieved without completely eliminating the donor miwater provided ad libitum. gratory cells (30) . Because the CD28/B7 and CD40/ Bone Marrow Transplantation CD40 ligand (CD40L) T-cell costimulatory pathways are important during T-cell activation (8, 21, 46) and are BALB/c recipients received 300 rad of total body irradiation (TBI) as a single dose on day 0, 6 h prior to involved in allograft rejection (11,15), costimulatory blockade, which can lead to antigen desensitization, an-BMTx. BM cells were flushed from the femurs and tibias of donor CBA/J mice with a 25-guage needle and ergy, or clonal deletion, can be employed as a component of the host-conditioning regimen to provide a strategy for filtered through a 70-µm nylon cell strainer (Becton Dickinson Labware, Franklin Lakes, NJ). Unfraction-maintaining this balance. Costimulatory blockade of the CD28/B7 and CD40/CD40L coreceptor/ligand interac-ated BM cells (2.7 × 10 7 ) in 500 µl phosphate-buffered saline (PBS) were administered IV into the sublethally tions has been utilized previously to successfully induce long-term graft survival and a state of DST in both ro-irradiated BALB/c recipients. The human chimeric fusion protein CTLA4-Ig, a generous gift from Dr. Robert dent and large-animal models (3, 17, 20, 22, 23, 27, 35) . Neither the discrete use of CTLA4-Ig nor anti-CD40L Peach (Bristol-Myers Squibb, Inc., Princeton, NJ), alone or in combination with MR1 hamster anti-mouse CD40L monoclonal antibody (mAb) has been particularly effective in allogeneic or xenogeneic models of Tx (3, 11, 45) .
IgG was administered at 250 or 500 µg IP on days 0, 2, 4, and 6 post-Tx. Controls included the L6 chimeric fu-Only when both reagents were used in combination was DST achieved (17, 20, 35) . Nevertheless, the effective-sion protein and hamster IgG, respectively. Recombinant human Flt3-L (10 µg), kindly provided by Im-ness of costimulatory blockade in preclinical models of DST has not been, to date, successfully translated to munex Corporation (Seattle, WA), was administered IP on days 0-6 post-Tx to the indicated treatment groups. clinical Tx.
The use of CTLA4-Ig and anti-CD40L mAb as a part Six mice, included in each experimental group, were monitored daily for changes in body weight and for vi-of the host-conditioning regimen prior to BMTx has led to the evolvement of less toxic protocols for the estab-sual manifestations of GVHD.
Skin Grafting
Statistical analysis was performed with a two-tailed t-test for independent samples with Levine's test for equality Donor CBA/J and third-party C57BL/6 full-thickness of variance (SPSS, Chicago, IL). tail skin approximately 6 mm in length was grafted on the dorso-lateral thoracic wall of chimeric BM allograft TCR Cross-Linking recipients or naive BALB/c controls, covered with vase-For assessing proliferation via CD3 and Vβ6 TCR line-impregnated gauze and secured with surgical tape. cross-linking, 2.5 × 10 5 responder cells from naive BALB/c After 8-9 days post-skin Tx, the bandages were reor BMTx recipients were stimulated in a 96-well round moved and the grafts were monitored by daily visual bottom plate for 72 h; the wells had been coated with inspection. Rejection was defined as the complete loss 2C11 hamster anti-mouse CD3 IgG or RR4-7 rat antiof viable tissue.
mouse Vβ6 TCR IgG 2b (Pharmingen) at 20 µg/ml in 100 Detection of Chimerism by Flow Cytometric Analysis µl of PBS for 1 h at room temperature, and subsequently washed three times with complete media. Eighteen hours The engraftment of donor-derived BM cells and the prior to the termination of culture, wells were pulsed percentage of donor cell chimerism in the BM transplant with 1.0 µCi [ 3 H]thymidine, harvested, and quantitated recipients were determined on days 30-90 post-Tx by using a scintillation counter. Results are expressed as three-color flow cytometric analysis. Peripheral blood mean cpm ± SEM. Statistical analysis was performed leukocytes were isolated from whole heparinized blood with a two-tailed t-test for independent samples with by Ficoll-Paque TM (Amersham Pharmacia, Uppsala, Swe-Levine's test for equality of variance (SPSS). den). In addition, spleens were removed and gently dissociated into single-cell suspensions, while BM was Detection of Vβ6 + and Vβ8 + Cells by Flow harvested as described above. Red blood cells were Cytometric Analysis eliminated with Tris:NH 4 Cl lysis. Cell washes and anti-Peripheral blood leukocytes from naive BALB/c or body dilutions were performed in cold PBS containing chimeric recipients were isolated, stained, and analyzed by 1% bovine fetal calf serum and 0.05% sodium azide.
flow cytometry as described above. Briefly, the presence Cells (1 × 10 5 /well) were blocked for nonspecific bindof Vβ6 + and Vβ8 + TCR was determined on the CD4 + T ing with 10% normal goat serum for 30 min at 4°C. The cells stained with PE-conjugated rat anti-mouse CD4 presence of donor (CBA/J) H-2 k cells was determined (Pharmingen). Vβ6 and Vβ8 subpopulations were stained within the leukocyte population of all three compartwith FITC-conjugated rat anti-mouse Vβ6 or Vβ8 (Pharments by staining the CD45 + cells with Cychrome TM rat mingen), respectively. Irrelevant isotype-matched control anti-mouse CD45 IgG 2b (1:400) (Pharmingen, San Diego, mAbs (Pharmingen) were used as negative controls. CA). Donor and recipient leukocytes were stained with Results are expressed as the percent of CD4 + Vβ6 + or fluorescein isothiocyanate (FITC)-conjugated rat anti-CD4 + Vβ8 + cells stained above background. mouse H-2K k (1:400) and phycoerythrin (PE)-conjugated rat anti-mouse H-2D d (1:400) mAbs, respectively. Irrele-RESULTS vant isotyped-matched mAbs at the same dilutions were Sublethal Irradiation and Costimulatory Blockade used as negative controls. Flow cytometric analysis was Promoted Donor Cell Chimerism performed using an EPICS Elite Cytometer (Beckman-In order to develop a strategy that would generate Coulter, Hialeah, FL). Results are expressed as the perdonor cell chimerism and possibly lead to DST, we emcent of CD45 + cells stained above background. Statistiployed a sublethal preconditioning regimen of TBI with cal analysis was performed with a two-tailed Fisher's subsequent infusion of donor BM cells and perioperative exact test of independence.
inhibition of the CD28/B7 and CD40/CD40L coreceptor One-Way Mixed Lymphocyte Reaction (MLR) interactions with costimulatory blockade. The dose and timing for the administration of CTLA4-Ig and MR1 Responder splenocytes from naive BALB/c or BMTx recipients were T cell enriched by nylon wool purification were determined from previous studies in our laboratory where these parameters had been optimized in murine and cocultured with an equal concentration (2 × 10 5 cells/ well) of γ-irradiated (2000 rad) donor-specific (CBA/J) or models of aortic and pancreatic islet allo-Tx (25, 26, 34, 36) . BM recipients were initially administered discrete third-party (C57BL/6) splenic stimulators in triplicate for 4 days. Controls included wells containing media alone or concurrent doses of CTLA4-Ig and MR1 at 250 µg on days 0, 2, 4, and 6 post-Tx, and evaluated for the or syngeneic (BALB/c) stimulators. The wells were pulsed with 1 µCi of [ 3 H]thymidine 18 h prior to the termina-presence of donor cell engraftment. Either agent alone or isotype-matched controls in this model failed to in-tion of culture, harvested onto glass fiber filters, and incorporation quantitated by scintillation counting. Results duce donor cell engraftment within the peripheral blood (0/4) when examined on days 30 and 90 post-Tx. How-are expressed as mean counts per minute (cpm) ± SEM. ever, when administered contemporaneously, 2/9 (22%) spleen and BM with chimerism being detected at the level of 28-46% (Table 2 , Fig. 1 ) and 7-16% (Table  of the recipients, receiving low-dose costimulatory blockade, engrafted donor-derived cells with 31-36% of the 2), respectively. No chimerism was detected in the third mouse of the CTLA4-Ig and MR1-treated group. Chi-CD45 + peripheral blood leukocytes being of donor origin (data not shown). From these pilot studies, it became merism was not detected in the CTLA4-Ig, MR1, or untreated allograft recipients ( Table 2) . On day 68 post-Tx, apparent that a higher dose of CTLA4-Ig and MR1 would be necessary to achieve a higher percentage of engraft-the three remaining allograft recipients in the combined CTLA4-Ig and MR1-treated group from this experiment ment and donor cell chimerism in the BM recipients.
To begin evaluating the contribution of a higher dose were evaluated for donor cell engraftment. Donor cell chimerism (17%) was detected in 1/3 (33%) when ana-of CD28/B7 and CD40/CD40L costimulatory blockade on the engraftment of donor BM in BALB/c recipients lyzing the CD45 + leukocytes in the peripheral blood (data not shown). It can be concluded that of the six preconditioned with sublethal irradiation, CTLA4-Ig and MR1 were administered discretely and concurrently at allograft recipients within the CTLA4-Ig and MR1treated group, three (50%) were chimeric at some point 500 µg on days 0, 2, 4, and 6 post-Tx, and engraftment of donor-derived cells and chimerism were evaluated in during the 68 days of evaluation post-Tx (Table 1 ). the peripheral blood by flow cytometry on day 30 post-Flt3-L Enhanced the Engraftment of Donor BM Cells Tx. No CD45 + leukocytes of donor origin were detected in the Peripheral Blood of the Combined CTLA4-Ig in the peripheral blood of untreated or CTLA4-Ig-or and MR1-Treated Allograft Recipients MR1-treated BM recipients (Table 1) . However, 5/12 (42%) of the combined CTLA4-Ig and MR1-treated re-Because Flt3-L is a growth factor with the potential to recruit and induce expansion of hematopoietic pro-cipients in two experiments (n = 6 mice/experiment) engrafted donor-derived cells with the level of chimerism genitor cells (1), the addition of this molecule in vivo seemed to be a feasible approach for enhancing engraft-being detected at 7-42% (Table 1) .
On day 54 post-Tx, three allograft recipients in one ment of donor-derived BM cells in sublethally irradiated BALB/c recipients. The recipients receiving Flt3-L (10 complete experiment were randomly selected from each group (n = 6/group), sacrificed, and analyzed by flow µg) on days 0-6 alone or in combination with CTLA4-Ig or MR1 failed to engraft donor-derived BM cells when cytometry for chimerism in the peripheral blood, spleen, and BM. In the CTLA4-Ig and MR1-treated group, the examined by flow cytometry on days 30-90 post-Tx (Table 1) . Nevertheless, as anticipated, a higher inci-mouse found chimeric on day 30 remained so when evaluated on day 54 post-BMTx. An additional mouse in this dence of donor BM engraftment was witnessed in recipients receiving Flt3-L with the combination of CTLA4-group was also found chimeric when the peripheral blood was evaluated on day 54; the level of chimerism Ig and MR1 when compared with the group receiving only CTLA4-Ig and MR1 on day 30 post-Tx during the ranged between 21% and 31% ( Table 2 ). The two mice, which were chimeric in the peripheral blood, also con-initial period of evaluation. Of these recipients, 8/13 (42%) engrafted BM with the level of chimerism being tained CD45 + leukocytes of donor origin in both the 
CD45 + leukocytes from allogeneic BM recipients treated with costimulatory blockage (500 µg) and Flt3-L were evaluated by flow cytometry on day 54 post-Tx for the engraftment of donor BM cells and the establishment of donor cell chimerism. Percent chimerism represents the total percent positive staining above background. n denotes the number of mice in each experimental group.
detected at 3-50%. Chimerism was detected at 3-70% evaluated within all three immune compartments for donor cell chimerism on day 54 post-Tx. All recipients in 10/13 (77%) of the recipients receiving Flt3-L in combination with CTLA4-Ig and MR1 on days 54-90 (3/3; 100%) receiving Flt3-L with the combination of CTLA4-Ig and MR1 contained donor CD45 + peripheral post-Tx. However, due to the relatively smaller sample size, this higher incidence of donor BM engraftment in blood leukocytes with the level of chimerism being detected at 5-31% ( Table 2 ). The two mice within this the recipients receiving Flt3-L with the combination of CTLA4-Ig and MR1 failed to reach statistical signifi-group that had been chimeric in the peripheral blood on day 30 were also chimeric within the spleen and BM on cance when compared with the recipients receiving only CTLA4-Ig and MR1 on day 30 (p = 0.554; Fisher's ex-day 54 post-Tx with 18-24% and 3-8%, respectively, of the CD45 + leukocytes being of donor origin ( Table 2 , act test of independence) or days 54-90 (p = 0.514) post-Tx. Fig. 1 ). The three remaining BM recipients from the original six were evaluated on day 68 post-Tx for the Three allograft recipients receiving Flt3-L in combination with CTLA4-Ig and MR1 from one complete engraftment of donor cells and for the establishment of chimerism. Only 1/3 (33%) remaining recipients was experiment (n = 6/group) were selected, sacrificed, and analyzed by flow cytometry for chimerism in the periph-chimeric (2.3%; data not shown). Taken together, 67% (4/6) of the recipients receiving contemporaneous ad-eral blood, spleen, and BM. Two of these three mice had been chimeric on day 30 post-Tx. Another mouse ministration of CTLA4-Ig, MR1, and Flt3-L exhibited donor cell chimerism at some point during the 68 days in this group and three randomly selected mice in the other experimental groups were selected, sacrificed, and of evaluation. Chimeric BM Recipients Treated With CTLA4-Ig, ing factor in its clinical applicability (38), it was imperative to explore the possibility of development of GVHD MR1, and Flt3-L Were Tolerant to Donor-Specific Skin Grafts in our approach for generating chimerism and inducing DST with sublethal irradiation and the contemporaneous In order to determine if the donor cell chimerism esadministration of CTLA4-Ig, MR1, and Flt3-L. In additablished in the recipients receiving the combination of tion to daily visual inspection, body weight was moni-CTLA4-Ig and MR1 with or without Flt3-L was accomtored daily for the initial 2 weeks following BMTx and panied by the induction of DST, donor-specific and at least once a week thereafter for all the animals in each third-party skin Tx were performed on days 32-40 post-BMTx. The chimeric CTLA4-Ig and MR1-treated BM recipients were tolerant to donor-specific alloantigens first set fashion (data not shown). tion following allogeneic BMTx and the foremost limit-FLT3-L AUGMENTS BONE MARROW ENGRAFTMENT 153 experimental group. With the exception of the untreated gens, the responders from untreated, sublethally irradiated BM recipients had a significantly suppressed donor-and CTLA4-Ig-treated recipients, the recipients in the remaining experimental groups had a slight reduction in specific proliferative response when compared with the naive BALB/c responders (p < 0.001) ( Fig. 3) , suggest-body weight initially following TBI and BM infusion. However, the body weight returned to the pre-Tx values ing that sublethal TBI and previous exposure to the alloantigens were responsible for this outcome. Responders within the 4 weeks of evaluation post-Tx (Fig. 2) . The untreated and CTLA4-Ig-treated recipients had an initial from recipients receiving CTLA4-Ig, MR1, or Flt3-L alone had significantly increased proliferative responses increase in body weight following TBI and BM infusion, with the loss of body weight being delayed until week to donor-specific alloantigen stimulation (p < 0.001) when compared with the untreated controls ( Fig. 3) . Similar 3 post-Tx and a return to normal by week 4 (Fig. 2) .
results were also obtained from the group receiving com-In Vitro Donor-Specific Proliferative Responses bined administration of CTLA4-Ig and Flt3-L. On the Were Unaltered in the Chimeric BM Recipients contrary, when CTLA4-Ig was combined with MR1 or both MR1 and Flt3-L, no appreciable increase in donor-To begin delineating the immunological mechanisms involved in the engraftment of BM and in the establish-specific proliferation occurred when compared with the untreated controls ( Fig. 3) . Likewise, no alterations were ment of donor cell chimerism, the in vitro proliferative responses to donor-specific (CBA/J) alloantigens were detected in the proliferative response of the combined MR1 and Flt3-L-treated group when compared with the evaluated on day 54 post-Tx by MLR. The splenocytes from three of the allograft recipients in each group (the untreated controls. These data suggest that the proliferative status of both chimeric groups (CTLA4-Ig and MR1; same three mice evaluated by flow cytometry on day 54) were pooled and nylon wool enriched for T cells.
CTLA4-Ig, MR1, and Flt3) was unaltered when compared with the nonchimeric untreated control, thereby When stimulated in vitro with donor-specific alloanti- failing to provide an explanation for the engraftment of 4). Responders from recipients receiving CTLA4-Ig, MR1, or Flt3-L had increased proliferative responses when the allogeneic BM. However, the increased proliferative responses of the nonchimeric experimental groups may stimulated through the Vβ6 TCR compared with the untreated control (Fig. 4) . Similar results were also wit-have contributed to the failure of allogeneic BM engraftment and the detection of chimerism in these groups.
nessed when stimulating responders from the combined CTLA4-Ig and Flt3-L or the combined MR1 and Flt3-Chimeric Recipients Exhibited Hyporesponsive L-treated groups (Fig. 4) . However, the responders from Vβ6-Stimulated Proliferation and the Deletion the chimeric CTLA4-Ig and MR1-treated groups with or of Vβ6 + CD4 + T Cells without Flt3-L had suppressed proliferative responses to stimulation through the Vβ6 TCR when compared with Careful selection of the donor and recipient combination utilized in this study allowed us to determine the the untreated control (Fig. 4) . Even though this hyporesponsiveness failed to reach statistical significance (p < fate and responsiveness of donor-reactive recipient T cells following BMTx. Because CBA/J donors are Vβ6 − 0.065 and p < 0.052, respectively), it is rational to contemplate that these changes may have contributed to the and BALB/c recipients are Vβ6 + , the ability of the recipient responders to become activated/deleted in the pres-engraftment of allogeneic BM and to the establishment of donor cell chimerism. ence of donor stimulators could be determined. On day 54 post-Tx, splenocytes were pooled (the three recipi-To determine the mechanism responsible for the in vitro hyporesponsiveness of the chimeric responders ents evaluated for chimerism by flow cytometry) in each group and were nonspecifically stimulated through cross-when stimulated through the Vβ6 TCR, further studies were conducted 60 days post-Tx using responder spleno-linking with plate-bound anti-Vβ6 mAb. Plate-bound anti-CD3 mAb was used as a positive control to confirm that cytes from the combined CTLA4-Ig and MR1-treated chimeric recipients. In vitro suppressor assays were un-the T cells were capable of being activated by signals initiated through the TCR. Responder splenocytes from yielding, suggesting that the generation of suppressor cells could be eliminated as a possibility for the ob-the BM recipients of all the experimental groups exhibited elevated responsiveness to anti-CD3 mAb stimula-served hyporesponsiveness and for the engraftment of allogeneic BM (data not shown). Therefore, to explore tion when compared with the naive BALB/c control (Fig. 4) . In contrast, responders from the BM (alone) the possibility of a deletional mechanism, the TCR-Vβ repertoire in the peripheral blood of the chimeric recipi-recipients, when stimulated with anti-Vβ6 mAb, had significantly suppressed proliferative responses when com-ent was assessed. The percentage of CD4 + T cells expressing the Vβ6 TCR was reduced in the chimeric pared with the naive BALB/c control (p < 0.001) ( Fig.  Figure 4 . Proliferative responses to Vβ6 TCR cross-linking in allogeneic BM recipients. Splenocytes from naive BALB/c or allogeneic BM recipients treated with costimulatory blockade with or without Flt3-L were stimulated in culture with plate-bound anti-Vβ6 mAb. Controls included responders stimulated with plate-bound anti-CD3 mAb. Proliferation was determined on day 3 of culture. Results are expressed as mean cpm ± SEM.
CTLA4-Ig and MR1-treated group (Fig. 5 ), suggesting gested that promoting cell trafficking between the donor and recipient, while maintaining an immunological bal-that the hyporesponsiveness and the presence of donor cell chimerism were directly related to the deletion of ance, may prevent GVHD and allograft rejection and lead to the induction and maintenance of DST (30, 38) . anti-donor-reactive Vβ6 + CD4 + T cells, while maintaining normal percentages of Vβ8 + CD4 + T cells when Conditioning the recipient for the acceptance of allogeneic BM has the potential to provide the stability re-compared with the naive BALB/c control (Fig. 5) . These data suggest that DST generated through the establish-quired between the donor and recipient to promote the engraftment of allogeneic BM, the establishment of do-ment of donor cell chimerism in this model may be due to clonal deletion of alloreactive T cells.
nor cell chimerism, and ultimately the induction of DST. The major limitation to developing a clinical protocol DISCUSSION for the induction of mixed chimerism has been associated with the toxicity of host conditioning, which is Since the initial reports detecting the presence of donor-derived BM cells in various lymphoid and nonlym-needed to achieve stable, long-term engraftment of allogeneic BM (38). Lethal irradiation, an undesirable and phoid tissues of kidney and liver recipients (30-32), many strategies have been employed, both clinically and toxic form of clinical preconditioning due to the elevated risk of malignancies and GVHD, can be avoided experimentally, for enhancing microchimerism within allograft recipients as a method for influencing graft sur-by using less toxic and nonmyeloablative conditioning protocols for the establishment of BM chimeras (38). vival and inducing DST (14, 24, 38) . The infusion of donor BM as an approach for achieving this outcome has Consequently, a relatively mild sublethal, nonmyeloablative regimen of TBI (300 rad) was chosen for recipi-been utilized with mixed success (14,38). The cell migration that occurs following infusion between the donor ent preconditioning in our murine, MHC-incompatible model of BMTx. However, the use of irradiation alone BM and the recipient's immune system, which is influenced by the quality of immunosuppression employed, in our model was insufficient for the engraftment of allogeneic BM. Therefore, contemporaneous perioperative the type of immune cells within the BM or transplanted organ, donor-recipient histoincompatibility, and per-blockade of the CD28/B7 and CD40/CD40L T-cell costimulatory pathways with CTLA4-Ig and MR1, respec-haps many undefined factors, can lead to either allograft rejection or acceptance (30) . Previous studies have sug-tively, was employed during the time of T-cell reconsti- tution following allogeneic BM infusion to reduce the allogeneic BM cells within our model required not only sublethal irradiation but also four doses of CTLA4-Ig number of potentially alloreactive T cells within the recipient. This strategy of sublethal TBI with subsequent and MR1. The fewer doses in the former study may be attributed to the utilization of a weaker MHC-incompati-infusion of donor BM cells and perioperative, contemporaneous inhibition of the CD28/B7 and CD40/CD40L ble strain combination when compared with the strain combination used in our study (43) . A recent study from T cell costimulatory pathways promoted the engraftment of allogeneic BM, established robust and stable donor the same laboratory has demonstrated the induction of DST with one dose of CTLA4-Ig and MR1 without the cell chimerism, and induced DST.
Previous reports have supported the importance of need for recipient conditioning (39) . However, it should be noted that an extremely large dose (2 × 10 8 ) of BM BMTx and costimulatory blockade for the induction of DST (4, 6, 7, 9, 12, 16, 18, 19, 28, (39) (40) (41) (42) (43) . Blockade of the cells was required for engraftment, and with this protocol, not all of the BMTx recipients retained a stable state CD28/B7 and CD40/CD40L T cell costimulatory pathways with a single dose of anti-CTLA4 and/or anti-CD40L of chimerism. Those "transient" mice, where chimerism plummeted over time, lacked DST, which was evident mAb with 700 rad TBI and allogeneic BM cells (3 × 10 7 ) enhanced chimerism in diabetic-prone NOD mice by the rejection of donor-specific skin grafts (39) . Even though this approach of blocking T costimulatory path- (6) . Due to their inherent radiation resistance, these mice, unlike our allogeneic inbred strains, required a larger ways without recipient conditioning demonstrated a majority of the recipients developing multilineage chime-dose of TBI for host conditioning. Sublethal irradiation with a single dose of CTLA4-Ig and MR1 has been rism and DST and seemed to be the mildest strategy of targeting donor-reactive T cells without nonspecific shown to result in the peripheral deletion of donor-reactive T cells and in the induction of DST in a murine immunosuppression or the destruction of the remaining T cell repertoire (39) , this approach may not be feasible model of BMTx (43) . On the contrary, engraftment of in humans and large-animal models, where chimerism is ing BM and tacrolimus alone (2) , which was attributed to the augmentation in the number of donor and recipi-more difficult to achieve than in rodent models (16, 38) . Stable chimerism in random bred, MHC-identical dogs ent antigen-presenting cells as a result of an allostimulatory effect that led to an immunological imbalance be-using a nonmyeloablative protocol with a limited course of immunosuppression after BMTx has been achieved;
tween the donor and recipient and to the rejection of the cardiac allografts (2) . These studies collectively support however, this approach has not been successful across MHC-disparate barriers (33) . Our strategy of using non-the therapeutic potential of hematopoietic growth factors and cytokines such as Flt3-L to enhance engraftment of myeloablative recipient conditioning with costimulatory blockade exhibits the potential to be a safe and feasible allogeneic BM in the peripheral blood and positive graft outcome when utilized under certain conditions. protocol for clinical organ transplant recipients. No evidence of significant weight loss, GVHD, or other com-So that we could evaluate the immunological mechanisms responsible for the induction of DST, a highly plications was observed within our model. The acceptance of donor-specific and the rejection of third-party immunogenic and MHC-incompatible strain combination was carefully selected. CBA/J (H-2 k , Mls d , Vβ6 − / skin grafts in our chimeric recipients demonstrated that DST had been achieved.
Vβ8 + TCR) and BALB/c ByJ (H-2 d , Mls c , Vβ6 + /Vβ8 + TCR) were chosen as donor and recipients, respectively. Growth factors and cytokines are capable of regulating the proliferation and differentiation of hematopoietic
The T-cell repertoire of the donor CBA/J has been deleted of Vβ6 + TCR, which is specific for the minor lym-cells and have been used in both human and experimental animal models of BMTx to promote reconstitution phocyte antigen-d (Mls d ). On the contrary, the recipient BALB/c is devoid of Mls d but consists of the Vβ6 + TCR, of hematopoietic stem cells and to augment chimerism. Because Flt3-L is one such hematopoietic growth factor which can recognize and bind to the Mls d of the donor. Splenic T cells from chimeric recipients treated with with the potential to recruit and induce expansion of hematopoietic stem and progenitor cells (1) and has con-CTLA4-Ig and MR1 with or without Flt3-L proliferated in vitro in response to donor-specific alloantigens. How-tributed to multilineage reconstitution in sublethally irradiated mice (5) , this molecule was administered in vivo ever, the proliferative responses were significantly suppressed when compared with the naive controls but were as an approach for enhancing engraftment of allogeneic BM cells. The addition of Flt3-L to our sublethal irradia-unaltered when compared with the untreated recipients, suggesting that the observed T-cell responsiveness was tion and costimulatory blockade protocol augmented the number of recipients that engrafted allogeneic BM cells due to the sublethal irradiation of the recipients rather than to the blockade of the costimulatory pathways and within the peripheral blood early post-Tx, and the chimerism remained stable throughout the period of evaluation.
the administration of Flt3-L. Similarly, when splenocytes from chimeric recipients were added to a primary Previous reports have demonstrated that the administration of Flt3-L in vivo for 5 days resulted in a significant culture, no alterations in T-cell proliferation were observed, which suggests that suppression was not a con-increase in the number of progenitors within the BM (fivefold), spleen (110-fold), and peripheral blood (200-tributor in our model to mixed chimerism or in the induction of DST. In contrast to the observed outcome, 300-fold) (5) . However, in our model, Flt3-L seemed to provide no enhancement of chimerism within the spleen Hale and colleagues demonstrated the involvement of active suppression when recipients were treated with or BM of the recipients. Conflicting data have been published as to the effectiveness of Flt3-L when adminis-ALS, sirolimus, and BM cells for the indefinite survival of skin allografts and for the induction of DST (10). tered in conjunction with immunosuppressive agents. A short course of Flt3-L to noncytoablated allogeneic BM However, when splenocytes from chimeric recipients within our study were stimulated in vitro through the recipients receiving tacrolimus exhibited increased levels of microchimerism in the recipient lymphoid tissue Vβ6 + TCR, the T-cell proliferative responses were suppressed, suggesting that the Vβ6 + T cells within the re-(13). In our model, the addition of Flt3-L to costimulatory blockade increased engraftment in the peripheral cipient that were specific for Mls d of the donor had been deleted. Flow cytometric analysis of the peripheral blood; however, no notable differences were detected in the levels of chimerism when compared with costimula-blood from the CTLA4-Ig and MR1-treated chimeric recipients confirmed that these donor-specific Vβ6 + T tory blockade alone until several months post-Tx. Nevertheless, the chimeric recipients generated via sublethal cells had been deleted. These data imply that the stability of the donor cell chimerism and the robustness of irradiation, costimulatory blockade, and Flt3-L in our model were tolerant to donor-specific skin grafts. Quite DST were achieved by the elimination of preexisting donor-specific T cells with the conditioning regimen and the reverse of our results, heart allograft recipients receiving BM, tacrolimus, and Flt3-L exhibited an acceler-that the newly developing thymocytes were being deleted within thymus, resulting in the absence of the do-ated rejection when compared with the recipients receiv- 
